Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462 · cited 1×
“miRNAs are short (18–25 nucleotides), noncoding RNA that regulate gene expression by inhibiting messenger RNA (mRNA) translation or affecting mRNA degradation.(14) Recent studies suggest that several diseases, including neurodegenerative disorders, are associated with the altered expression of miRNAs.”
BackgroundMicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
MicroRNA as Biomarkers and Diagnostics
Wang, J., Chen, J., & Sen, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25056 · Cited by 793 · cited 1×
“In addition, specific miRNAs are known to differentiate healthy versus disease states, and this has led to testing miRNAs as diagnostic biomarkers in the clinic for cardiovascular, neurological, and pulmonary disorders and various types of cancer.(19,20) We sought to identify miRNAs differentially expressed in serum s…”
BackgroundEvaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study
Mestdagh, P., Hartmann, N., Baeriswyl, L., Andreasen, D., Bernard, N., Chen, C., Cheo, D., D'Andrade, P., DeMayo, M., Dennis, L., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3014 · Cited by 660
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451 · cited 1×
“Both treatments appear to be more effective when started early in the disease.(2,4) Hence, the current average diagnostic delay of approximately 12 months is potentially deleterious.”
BackgroundMethod for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt261 · Cited by 236 · cited 11×
“Among the 23 patients with ALS enrolled, 3 had fALS and 20 had sALS.”
BackgroundInfluentialCirculating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208 · cited 1×
“Recent studies suggest that several diseases, including neurodegenerative disorders, are associated with the altered expression of miRNAs.(15) Consistent with this, differentially expressed miRNAs have been identified in plasma, serum, spinal cord, and cerebrospinal fluid (CSF) of patients with ALS.”
Background
Cited by
Liguori, M., Nuzziello, N., Introna, A., Consiglio, A., Licciulli, F., D’Errico, E., Scarafino, A., Distaso, E., & Simone, I. L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00288 · Cited by 131
“The discordance in the expression between intronic miRNAhost mRNA pairs could be explained by the occurrence of an alternative splicing event in the region of clustered miRNAs (Ramalingam et al., 2014).”
BackgroundSaucier, D., Wajnberg, G., Roy, J., Beauregard, A.-P., Chacko, S., Crapoulet, N., Fournier, S., Ghosh, A., Lewis, S. M., Marrero, A., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2018.12.016 · Cited by 119
Ravanidis, S., Bougea, A., Papagiannakis, N., Maniati, M., Koros, C., Simitsi, A., Bozi, M., Pachi, I., Stamelou, M., Paraskevas, G. P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27928 · Cited by 51
MicroRNA signatures in genetic frontotemporal dementia and amyotrophic lateral sclerosis
Kmetzsch, V., Latouche, M., Saracino, D., Rinaldi, D., Camuzat, A., Gareau, T., the French Research Network on FTD/ALS, Le Ber, I., Colliot, O., & Becker, E. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51674 · Cited by 17
Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
Ryu, I. S., Ha, D.-I., Jung, Y.-J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020615 · Cited by 2
“For example, Raheja and colleagues reported 7 upregulated miRNAs (including miR-192-5p, miR-1, and miR-133a-3p) and 6 downregulated miRNAs (including miR-320c and miR-320a) in the serum of ALS patients [20].”
Metadata
- Authors
- Raheja, R., Regev, K., Healy, B. C., Mazzola, M. A., Beynon, V., Von Glehn, F., Paul, A., Diaz‐Cruz, C., Gholipour, T., Glanz, B. I., Kivisakk, P., Chitnis, T., Weiner, H. L., Berry, J. D., & Gandhi, R.
- Venue
- Muscle & Nerve
- Publisher
- Wiley
- Published
- 2018-03-25
- Volume
- 58
- Issue
- 2
- Pages
- 261-269
- ISSN
- 0148-639X (ISSN-L)
- 1097-4598
- OpenAlex
- W2790872584
- Cited by
- 98
- References
- 11
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.